17 March 2020

The Oncode Compound Library: find new therapeutic applications that others missed

Elize Brolsma

Drug repurposing is an effective approach to rapidly identify novel indications for known drugs and compounds. In order to support researchers in bringing novel therapeutic applications to the patient at affordable costs, Oncode has obtained the next generation Drug Repurposing library, which contains more than 6.000 drugs in various stages of clinical development (abandoned, off-patent, launched, etc). The unique composition of the library is described in a publication of the Broad Institute in Nature Medicine.

The Drug Repurposing programme enables all Oncode researchers to have access to the library. Furthermore, Oncode will provide interested investigators with the technical infrastructure and expertise that is required to perform compound screens, even with a complex experimental setup.

We spoke with Oncode Investigator René Bernards (Netherlands Cancer Institute) who initially came up with the idea of acquiring the compound library for Oncode. He discusses the added value of this library for researchers and how they can make use of it.

René Bernards: “One of the reasons why I thought this library is of immense added value for Oncode, is that it could support our goal of making healthcare and drug development more affordable. For instance, if researchers find a new application for a drug that is already licenced for patient use, it would mean that we could clinically develop it further at a much faster pace and with less costs involved. In addition, most of the compounds in this library were only tested in a very limited setting, meaning not all possible applications were investigated. Oncode, as a scientific organisation, has broader research questions and hypotheses and has the knowhow and technology to screen for compounds in this library that act on a different range of phenotypes.

“As cancer researchers, we are interested in very specific processes. We want to know whether a process is activated or deactivated by a certain compound. For example, we are interested in targeting senescent cells and it can take up to 7 days before you see any results. It is therefore very likely that we pick up on active compounds which were initially missed by the pharmaceutical industry, as their assays are typically only 3-day assays.”

“The compound library is of great value to Oncode researchers. It really gives them the opportunity to do targeted research and find things that others missed before. As Oncode researchers, we focus on many different types of research and cancers and the library caters for this. This library provides an opportunity for researchers to really gain new insights for their research.”

“Finally, there are currently two centres of expertise within Oncode (the NKI and LUMC) with experts who can support researchers to optimize their assays, execute the screens, and analyse the data, so researchers that are normally not equipped to perform these screens, can now take it a step further.”

The Oncode compound library is now available for all Oncode Investigators. Please contact Jacqueline Staring if you are interested or would like to receive more information.

Jacqueline Staring Programme Manager

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.